Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Semaglutide and Tirzepatide — mechanism, dosing, side effects, legal status, and pricing.
Semaglutide is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It has become one of the most widely prescribed medications for obesity due to its significant weight-loss efficacy.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It represents a new class of dual-incretin therapy with superior weight-loss efficacy compared to single-agonist approaches.
Semaglutide
Tirzepatide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
The STEP clinical trial program demonstrated average weight loss of 15–17% body weight over 68 weeks. The SELECT trial showed a 20% reduction in major adverse cardiovascular events. Oral semaglutide (Rybelsus) is also FDA-approved for type 2 diabetes.
The SURMOUNT-1 trial demonstrated average weight loss of 22.5% at the highest dose over 72 weeks, surpassing semaglutide. HbA1c reductions were also superior in head-to-head trials. Cardiovascular outcome trials are ongoing.
Semaglutide and Tirzepatide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs